{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:50:38Z","timestamp":1790628638802,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01915-5","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:47:08Z","timestamp":1762843628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: a systematic review of monoclonal antibodies and fusion proteins in combination strategies"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9811-7754","authenticated-orcid":false,"given":"Wajahat","family":"Mirza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundas","family":"Dadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshan","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Junaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq Mahmood","family":"Satti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"2","key":"1915_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271\u201385. https:\/\/doi.org\/10.1016\/j.cell.2009.05.046.","journal-title":"Cell"},{"issue":"2","key":"1915_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286\u201399. https:\/\/doi.org\/10.1016\/j.cell.2009.05.045.","journal-title":"Cell"},{"issue":"2","key":"1915_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","volume":"24","author":"MP Chao","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R. The CD47\u2013SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24(2):225\u201332. https:\/\/doi.org\/10.1016\/j.coi.2012.01.010.","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"1915_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.it.2017.12.002","volume":"39","author":"A Veillette","year":"2018","unstructured":"Veillette A, Chen J. SIRP\u03b1\u2013CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol. 2018;39(3):173\u201384. https:\/\/doi.org\/10.1016\/j.it.2017.12.002.","journal-title":"Trends Immunol"},{"key":"1915_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","volume":"32","author":"AN Barclay","year":"2014","unstructured":"Barclay AN, van den Berg TK. The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32:25\u201350. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120142.","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"1915_CR6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, et al. First-in-human phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37(12):946\u201353. https:\/\/doi.org\/10.1200\/JCO.18.02018.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1915_CR7","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med. 2018;379(18):1711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1807315.","journal-title":"N Engl J Med"},{"issue":"18","key":"1915_CR8","doi-asserted-by":"publisher","first-page":"5279","DOI":"10.1158\/1078-0432.CCR-21-0725","volume":"27","author":"SM Ansell","year":"2021","unstructured":"Ansell SM, Maris MB, Lesokhin AM, et al. Phase 1 study of TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27(18):5279\u201387. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0725.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1915_CR9","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Al Malki MM, Asch AS, et al. Magrolimab plus azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J Clin Oncol. 2023;41(15):2815\u201326. https:\/\/doi.org\/10.1200\/JCO.22.01794.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1915_CR10","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1200\/JCO.22.02604","volume":"41","author":"N Daver","year":"2023","unstructured":"Daver N, Vyas P, Kambhampati S, et al. Tolerability and efficacy of magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results. J Clin Oncol. 2023;41(31):4893\u2013904. https:\/\/doi.org\/10.1200\/JCO.22.02604.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1915_CR11","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1182\/bloodadvances.2023010136","volume":"7","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Sekeres MA, List AF, et al. Magrolimab + azacitidine in TP53-mutant MDS and AML: phase 2 study. Blood Adv. 2023;7(12):2859\u201369. https:\/\/doi.org\/10.1182\/bloodadvances.2023010136.","journal-title":"Blood Adv"},{"issue":"22","key":"1915_CR12","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1182\/bloodadvances.2024013338","volume":"8","author":"JE Maakaron","year":"2024","unstructured":"Maakaron JE, Asch AS, Popplewell L, et al. Magrolimab plus rituximab with or without chemotherapy in relapsed\/refractory DLBCL. Blood Adv. 2024;8(22):5864\u201375. https:\/\/doi.org\/10.1182\/bloodadvances.2024013338.","journal-title":"Blood Adv"},{"issue":"22","key":"1915_CR13","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1182\/bloodadvances.2024013277","volume":"8","author":"A Mehta","year":"2024","unstructured":"Mehta A, Popplewell L, Collins GP, et al. Magrolimab plus rituximab in relapsed\/refractory indolent NHL: 3-year follow-up of a phase 1\/2 trial. Blood Adv. 2024;8(22):5855\u201363. https:\/\/doi.org\/10.1182\/bloodadvances.2024013277.","journal-title":"Blood Adv"},{"issue":"18","key":"1915_CR14","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1182\/bloodadvances.2023010144","volume":"7","author":"G Luscan","year":"2023","unstructured":"Luscan G, Borel C, Quittet P, et al. Magrolimab combined with the CD20xCD3 bispecific antibody glofitamab in relapsed\/refractory DLBCL: phase Ib\/II study. Blood Adv. 2023;7(18):5116\u201328. https:\/\/doi.org\/10.1182\/bloodadvances.2023010144.","journal-title":"Blood Adv"},{"issue":"1","key":"1915_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2217\/fon-2022-0975","volume":"19","author":"B Paul","year":"2023","unstructured":"Paul B, Liedtke M, Khouri J, et al. Magrolimab combinations in relapsed\/refractory multiple myeloma: phase II study. Future Oncol. 2023;19(1):7\u201317. https:\/\/doi.org\/10.2217\/fon-2022-0975.","journal-title":"Future Oncol"},{"issue":"24","key":"1915_CR16","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1182\/bloodadvances.2023012427","volume":"7","author":"N Hoyle","year":"2023","unstructured":"Hoyle N, Lin W, et al. Maplirpacept + tafasitamab and lenalidomide in relapsed\/refractory DLBCL. Blood Adv. 2023;7(24):5657\u201367. https:\/\/doi.org\/10.1182\/bloodadvances.2023012427.","journal-title":"Blood Adv"},{"issue":"9","key":"1915_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137345","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu J, Wang L, Zhao F, et al. Pre-clinical development of a humanized anti-CD47 antibody with therapeutic potential. PLoS ONE. 2015;10(9):e0137345. https:\/\/doi.org\/10.1371\/journal.pone.0137345.","journal-title":"PLoS ONE"},{"issue":"4","key":"1915_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations. Blood. 2017;129(4):424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"issue":"9","key":"1915_CR19","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2011-08-371971","volume":"119","author":"FG Rucker","year":"2012","unstructured":"Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in AML with complex karyotype. Blood. 2012;119(9):2114\u201321. https:\/\/doi.org\/10.1182\/blood-2011-08-371971.","journal-title":"Blood"},{"key":"1915_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.33","volume":"5","author":"HA Hou","year":"2015","unstructured":"Hou HA, Chou WC, Kuo YY, et al. TP53 mutations in de novo AML patients. Blood Cancer J. 2015;5:e331. https:\/\/doi.org\/10.1038\/bcj.2015.33.","journal-title":"Blood Cancer J"},{"issue":"19","key":"1915_CR21","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1002\/cncr.33640","volume":"127","author":"S Venugopal","year":"2021","unstructured":"Venugopal S, Shoukier M, Konopleva M, et al. Outcomes in TP53-mutated AML with or without venetoclax therapy. Cancer. 2021;127(19):3541\u201351. https:\/\/doi.org\/10.1002\/cncr.33640.","journal-title":"Cancer"},{"issue":"9","key":"1915_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24098","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR, et al. NHL subtype distribution and survival in the US: NCDB analysis. Am J Hematol. 2015;90(9):790\u20135. https:\/\/doi.org\/10.1002\/ajh.24098.","journal-title":"Am J Hematol"},{"key":"1915_CR23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2147\/OTT.S346557","volume":"15","author":"P Vodicka","year":"2022","unstructured":"Vodicka P, Klener P, Trneny M. Diffuse large B-cell lymphoma: emerging treatment options. OncoTargets Ther. 2022;15:1481\u2013501. https:\/\/doi.org\/10.2147\/OTT.S346557.","journal-title":"OncoTargets Ther"},{"issue":"S1","key":"1915_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/hon.3122","volume":"41","author":"AP Boardman","year":"2023","unstructured":"Boardman AP, Salles G. CAR T-cell therapy in large B cell lymphoma. Hematol Oncol. 2023;41(S1):112\u20138. https:\/\/doi.org\/10.1002\/hon.3122.","journal-title":"Hematol Oncol"},{"issue":"5","key":"1915_CR25","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00280-009-0945-7","volume":"64","author":"G Corazzelli","year":"2009","unstructured":"Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with or without rituximab. Cancer Chemother Pharmacol. 2009;64(5):907\u201316. https:\/\/doi.org\/10.1007\/s00280-009-0945-7.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1915_CR26","doi-asserted-by":"publisher","unstructured":"Joshua F, Zeidner David A, Sallman Christian, R\u00e9cher Naval G, Daver Anskar Y. H, Leung Devendra K, Hiwase Marion, Subklewe Thomas, Pabst Pau, Montesinos Richard A., Larson Lindsay, Wilde Anoop K, Enjeti Ichiro, Kawashima Cristina, Papayannidis Jenny, O\u2019Nions Lisa, Johnson Mei, Dong Julie, Huang Taravat, Bagheri Gal, Hacohen Kleiman Calvin, Lee Paresh, Vyas (2025) (2025)  Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study Blood 146(5) 590-600. https:\/\/doi.org\/10.1182\/blood.2024027408","DOI":"10.1182\/blood.2024027408"},{"key":"1915_CR27","doi-asserted-by":"crossref","unstructured":"Daver N, Vyas P, Huls G, D\u00f6hner H, Maury S, Novak J, Papayannidis C, Mart\u00ednez Chamorro C, Montesinos P, Niroula R, Fenaux P. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood. 2025 Jul 31;146(5):601-11.","DOI":"10.1182\/blood.2024027506"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01915-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:48:15Z","timestamp":1764917295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01915-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1915"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01915-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This article is based on previously published studies and does not involve any new studies of human or animal subjects performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"360"}}